Cartesian Therapeutics Inc (NAS:RNAC)
$ 18.83 0.92 (5.14%) Market Cap: 478.56 Mil Enterprise Value: 274.02 Mil PE Ratio: 0 PB Ratio: 607.42 GF Score: 52/100

Selecta Biosciences Inc at Bank of America Merrill Lynch Healthcare Conference (Virtual) Transcript

May 12, 2020 / 09:00PM GMT
Release Date Price: $96.6 (-2.13%)
Jason Matthew Gerberry
BofA Merrill Lynch, Research Division - MD in US Equity Research

Good day, everybody. Thank you for joining us. I'm sorry, operator, are you going to read some disclosures?

Operator

Yes, please. Hello. This webcast presentation is for Bank of America clients only. If you are a member or representative of the press or media, please disconnect now.

And now I would like to turn the call over to you, Jason. Thank you, and have a good day.

Jason Matthew Gerberry
BofA Merrill Lynch, Research Division - MD in US Equity Research

Great. Thank you, and thank you, everybody, for joining us today for our next company presenter at the Bank of America Virtual Health Care Conference. I'm pleased to be introducing Selecta Biosciences, Carsten Brunn, President and CEO of the company.

First off, Carsten, thank you for joining us. Selecta, for those of you on the call, is a clinical-stage biopharma company, focused on using its ImmTOR platform, which is really designed to induce tolerance to novel

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot